Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Miranda, Aline S ^a   Brant, Fátima ^a   Rocha, Natália P ^a   Cisalpino, Daniel ^a   Rodrigues, David H ^a   Souza, Danielle G ^a   Machado, Fabiana S ^a   Rachid, Milene A ^a   Teixeira, Antônio L ^a   Campos, Alline C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Artesunate; Cerebral malaria; Cytokines; Malaria; Memory impairment; Neuroinflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ARTESUNATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AVERSIVE BEHAVIOR; AVOIDANCE BEHAVIOR; BEHAVIOR CHANGE; BRAIN MALARIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; INOCULATION; LONG TERM MEMORY; MEMORY DISORDER; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OPEN FIELD TEST; PLASMODIUM BERGHEI; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REARING; SINGLE DRUG DOSE; SURVIVAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMALARIALS; ARTEMISININS; CYTOKINES; CYTOLOGICAL TECHNIQUES; DISEASE MODELS, ANIMAL; FEMALE; FRONTAL LOBE; GENE EXPRESSION PROFILING; HIPPOCAMPUS; MALARIA, CEREBRAL; MICE; MICE, INBRED C57BL; PLASMODIUM BERGHEI; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84886738912     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-388     Document Type: Article

References (38)

1. Severe falciparum malaria. World health organization. Communicable diseases cluster. Trans R Soc Trop Med Hyg 2000 94 Suppl 1 1 S90 11103309
2. The global distribution of clinical episodes of Plasmodium falciparum malaria. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, Nature 2005 434 214 217 10.1038/nature03342 15759000 (Pubitemid 40388051)
3. Neuroinflammation and brain infections: historical context and current perspectives. Bentivoglio M, Mariotti R, Bertini G, Brain Res Rev 2011 66 152 173 10.1016/j.brainresrev.2010.09.008 20883721
4. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Idro R, Jenkins NE, Newton CR, Lancet Neurol 2005 4 827 840 10.1016/S1474-4422(05)70247-7 16297841 (Pubitemid 41619438)
5. The 'hidden' burden of malaria: cognitive impairment following infection. Fernando SD, Rodrigo C, Rajapakse S, Malar J 2010 9 366 10.1186/1475-2875-9-366 21171998
6. Immunopathogenesis of cerebral malaria. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Medana IM, Miu J, Ball HJ, Int J Parasitol 2006 36 569 582 10.1016/j.ijpara.2006.02.016 16678181 (Pubitemid 43674512)
7. A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE, Trends Parasitol 2006 22 503 508 10.1016/j.pt.2006.09.002 16979941 (Pubitemid 44479847)
8. Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. Desruisseaux MS, Gulinello M, Smith DN, Lee SC, Tsuji M, Weiss LM, Spray DC, Tanowitz HB, J Infect Dis 2008 197 1621 1627 10.1086/587908 18419550 (Pubitemid 351706494)
9. Behavioural and histopathological alterations in mice with cerebral malaria. Lackner P, Beer R, Heussler V, Goebel G, Rudzki D, Helbok R, Tannich E, Schmutzhard E, Neuropathol Appl Neurobiol 2006 32 177 188 10.1111/j.1365-2990. 2006.00706.x 16599946
10. Anxiety-like behavior and proinflammatory cytokine levels in the brain of C57BL/6 mice infected with Plasmodium berghei (strain ANKA). de Miranda AS, Lacerda-Queiroz N, de Carvalho Vilela M, Rodrigues DH, Rachid MA, Quevedo J, Teixeira AL, Neurosci Lett 2011 491 202 206 10.1016/j.neulet.2011.01.038 21256928
11. Brain-derived neurotrophic factor and the course of experimental cerebral malaria. Linares M, Marin-Garcia P, Perez-Benavente S, Sanchez-Nogueiro J, Puyet A, Bautista JM, Diez A, Brain Res 2013 1490 210 224 23123703
12. Diagnosis and management of the neurological complications of falciparum malaria. Mishra SK, Newton CR, Nat Rev Neurol 2009 5 189 198 10.1038/nrneurol.2009.23 19347024
13. Artesunate for the treatment of severe falciparum malaria. Rosenthal PJ, N Engl J Med 2008 358 1829 1836 10.1056/NEJMct0709050 18434652 (Pubitemid 351581195)
14. Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. Cheng C, Ho WE, Goh FY, Guan SP, Kong LR, Lai WQ, Leung BP, Wong WS, PLoS One 2011 6 20932 10.1371/journal.pone.0020932 21695271
15. Anti-malarial drug artesunate ameliorates oxidative lung damage in experimental allergic asthma. Ho WE, Cheng C, Peh HY, Xu F, Tannenbaum SR, Ong CN, Wong WS, Free Radic Biol Med 2012 53 498 507 10.1016/j.freeradbiomed.2012. 05.021 22634146
16. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Jin O, Zhang H, Gu Z, Zhao S, Xu T, Zhou K, Jiang B, Wang J, Zeng X, Sun L, Cell Mol Immunol 2009 6 461 467 10.1038/cmi.2009.58 20003822
17. Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation. Li B, Li J, Pan X, Ding G, Cao H, Jiang W, Zheng J, Zhou H, Int Immunopharmacol 2010 10 344 350 10.1016/j.intimp.2009.12.006 20005985
18. Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Li Y, Wang S, Wang Y, Zhou C, Chen G, Shen W, Li C, Lin W, Lin S, Huang H, Liu P, Shen X, Transl Res 2013 161 89 98 10.1016/j.trsl.2012.06.001 22749778
19. Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain. Clemmer L, Martins YC, Zanini GM, Frangos JA, Carvalho LJ, Antimicrob Agents Chemother 2011 55 1383 1390 10.1128/AAC.01277-10 21220531
20. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Lou J, Clin Microbiol Rev 2001 14 810 820 table of contents 10.1128/CMR.14.4.810-820.2001 11585786 (Pubitemid 32979632)
21. L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria. Grau GE, Piguet PF, Engers HD, Louis JA, Vassalli P, Lambert PH, J Immunol 1986 137 2348 2354 3093572 (Pubitemid 16020735)
22. Slow and continuous delivery of a low dose of nimodipine improves survival and electrocardiogram parameters in rescue therapy of mice with experimental cerebral malaria. Martins YC, Clemmer L, Orjuela-Sanchez P, Zanini GM, Ong PK, Frangos JA, Carvalho LJ, Malar J 2013 12 138 10.1186/1475-2875-12- 138 23617605
23. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. Reis PA, Comim CM, Hermani F, Silva B, Barichello T, Portella AC, Gomes FC, Sab IM, Frutuoso VS, Oliveira MF, et al. PLoS Pathog 2010 6 1000963 10.1371/journal.ppat.1000963 20585569
24. Depressive-like-behavior and proinflamatory interleukine levels in the brain of rats submitted to pneumococcal meningitis. Barichello T, Dos Santos I, Savi GD, Simoes LR, Generoso JS, Comim CM, Sachs D, Teixeira AL, Quevedo J, Brain Res Bull 2010 82 243 246 10.1016/j.brainresbull.2010.04.015 20450961
25. A rapid murine coma and behavior scale for quantitative assessment of murine cerebral malaria. Carroll RW, Wainwright MS, Kim KY, Kidambi T, Gomez ND, Taylor T, Haldar K, PLoS One 2010 5 13124 doi:10.1371/journal.pone.0013124. 10.1371/journal.pone.0013124 20957049
26. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE, Mamm Genome 1997 8 711 713 10.1007/s003359900551 9321461 (Pubitemid 127739700)
27. Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. John CC, Panoskaltsis-Mortari A, Opoka RO, Park GS, Orchard PJ, Jurek AM, Idro R, Byarugaba J, Boivin MJ, Am J Trop Med Hyg 2008 78 198 205 18256412 (Pubitemid 351844547)
28. Persistent hijacking of brain proteasomes in HIV-associated dementia. Nguyen TP, Soukup VM, Gelman BB, Am J Pathol 2010 176 893 902 10.2353/ajpath.2010.090390 20035054
29. Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation. Dong C, Upadhya SC, Ding L, Smith TK, Hegde AN, Learn Mem 2008 15 335 347 10.1101/lm.984508 18441292 (Pubitemid 351629595)
30. Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Bingol B, Sheng M, Neuron 2011 69 22 32 10.1016/j.neuron.2010.11.006 21220096
31. Inflammatory changes in the central nervous system are associated with behavioral impairment in Plasmodium berghei (strain ANKA)-infected mice. Lacerda-Queiroz N, Rodrigues DH, Vilela MC, Miranda AS, Amaral DC, Camargos ER, Carvalho LJ, Howe CL, Teixeira MM, Teixeira AL, Exp Parasitol 2010 125 271 278 10.1016/j.exppara.2010.02.002 20138873
32. Artesunate in combination with oxacillin protect sepsis model mice challenged with lethal live methicillin-resistant Staphylococcus aureus (MRSA) via its inhibition on proinflammatory cytokines release and enhancement on antibacterial activity of oxacillin. Jiang W, Li B, Zheng X, Liu X, Cen Y, Li J, Pan X, Cao H, Zheng J, Zhou H, Int Immunopharmacol 2011 11 1065 1073 10.1016/j.intimp.2011.02.028 21396483
33. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation. Li B, Zhang R, Li J, Zhang L, Ding G, Luo P, He S, Dong Y, Jiang W, Lu Y, Cao H, Zheng J, Zhou H, Int Immunopharmacol 2008 8 379 389 10.1016/j.intimp.2007.10.024 18279792
34. Cytokine profile of murine malaria: stage-related production of inflammatory and anti-inflammatory cytokines. Bakir HY, Tomiyama C, Abo T, Biomed Res 2011 32 203 208 10.2220/biomedres.32.203 21673450
35. Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells. Lee IS, Ryu DK, Lim J, Cho S, Kang BY, Choi HJ, Neurosci Lett 2012 509 17 21 10.1016/j.neulet.2011.12.034 22227297
36. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, Epiphanio S, Chora A, Rodrigues CD, Gregoire IP, Cunha-Rodrigues M, Portugal S, Soares MP, Mota MM, Nat Med 2007 13 703 710 10.1038/nm1586 17496899 (Pubitemid 46889755)
37. A novel carbon monoxide-releasing molecule fully protects mice from severe malaria. Pena AC, Penacho N, Mancio-Silva L, Neres R, Seixas JD, Fernandes AC, Romao CC, Mota MM, Bernardes GJ, Pamplona A, Antimicrob Agents Chemother 2012 56 1281 1290 10.1128/AAC.05571-11 22155828
38. Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. Reis PA, Estato V, da Silva TI, d'Avila JC, Siqueira LD, Assis EF, Bozza PT, Bozza FA, Tibirica EV, Zimmerman GA, Castro-Faria-Neto HC, PLoS Pathog 2012 8 1003099 10.1371/journal.ppat.1003099 23300448